Answers are grounded in this paper and cite their sources.
Forteo (teriparatide of rDNA origin), a genetically engineered fragment of parathyroid hormone, is the first of a new class of drugs to treat osteoporosis. The drug's anabolic action increases bone turnover, stimulating osteoblasts to a greater extent than osteoclasts, and reducing both vertebral and nonvertebral fractures. However, a number of issues about its use remain unanswered.
No takes yet. Share an insight, caveat, or question.
Deal et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: